Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois; Gunnar Kristensen; Isabelle Ray-Coquard; Alexander Reuss; Sandro Pignata; Nicoletta Colombo; Ursula Denison; Ignace Vergote; Jose M Del Campo; Petronella Ottevanger; Martin Heubner; Thomas Minarik; Emmanuel Sevin; Nikolaus de Gregorio; Mariusz Bidziński; Jacobus Pfisterer; Susanne Malander; Felix Hilpert; Mansoor Raza Mirza; Giovanni Scambia; Werner Meier; Maria O Nicoletto; Line Bjørge; Alain Lortholary; Martin Oliver Sailer; Michael Merger; Philipp Harter; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium

doi:10.1016/S1470-2045(15)00366-6

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M Del Campo, Petronella Ottevanger, Martin Heubner, Thomas Minarik, Emmanuel Sevin, Nikolaus de Gregorio, Mariusz Bidziński, Jacobus Pfisterer, Susanne Malander, Felix Hilpert, Mansoor Raza Mirza, Giovanni ScambiaWerner Meier, Maria O Nicoletto, Line Bjørge, Alain Lortholary, Martin Oliver Sailer, Michael Merger, Philipp Harter, AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

124 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Lancet Oncology
Vol/bind	17
Udgave nummer	1
Sider (fra-til)	78-89
Antal sider	12
ISSN	1470-2045
DOI	https://doi.org/10.1016/S1470-2045(15)00366-6
Status	Udgivet - jan. 2016

Bibliografisk note

Medlem af Study group

Adgang til dokumentet

10.1016/S1470-2045(15)00366-6

Fingeraftryk Dyk ned i forskningsemnerne om 'Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

du Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., ... AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium (2016). Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, 17(1), 78-89. https://doi.org/10.1016/S1470-2045(15)00366-6

du Bois, Andreas ; Kristensen, Gunnar ; Ray-Coquard, Isabelle ; Reuss, Alexander ; Pignata, Sandro ; Colombo, Nicoletta ; Denison, Ursula ; Vergote, Ignace ; Del Campo, Jose M ; Ottevanger, Petronella ; Heubner, Martin ; Minarik, Thomas ; Sevin, Emmanuel ; de Gregorio, Nikolaus ; Bidziński, Mariusz ; Pfisterer, Jacobus ; Malander, Susanne ; Hilpert, Felix ; Mirza, Mansoor Raza ; Scambia, Giovanni ; Meier, Werner ; Nicoletto, Maria O ; Bjørge, Line ; Lortholary, Alain ; Sailer, Martin Oliver ; Merger, Michael ; Harter, Philipp ; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. / Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12) : a randomised, double-blind, placebo-controlled phase 3 trial. I: Lancet Oncology. 2016 ; Bind 17, Nr. 1. s. 78-89.

@article{e0d0f1121cad43fbaa9d261aa591e37a,

title = "Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial",

keywords = "Adult, Aged, Aged, 80 and over, Anemia, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Cytoreduction Surgical Procedures, Diarrhea, Disease Progression, Disease-Free Survival, Double-Blind Method, Fallopian Tube Neoplasms, Female, Humans, Indoles, Intention to Treat Analysis, Middle Aged, Neoplasm Staging, Neutropenia, Ovarian Neoplasms, Paclitaxel, Peritoneal Neoplasms, Response Evaluation Criteria in Solid Tumors, Thrombocytopenia, Young Adult, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",

author = "{du Bois}, Andreas and Gunnar Kristensen and Isabelle Ray-Coquard and Alexander Reuss and Sandro Pignata and Nicoletta Colombo and Ursula Denison and Ignace Vergote and {Del Campo}, {Jose M} and Petronella Ottevanger and Martin Heubner and Thomas Minarik and Emmanuel Sevin and {de Gregorio}, Nikolaus and Mariusz Bidzi{\'n}ski and Jacobus Pfisterer and Susanne Malander and Felix Hilpert and Mirza, {Mansoor Raza} and Giovanni Scambia and Werner Meier and Nicoletto, {Maria O} and Line Bj{\o}rge and Alain Lortholary and Sailer, {Martin Oliver} and Michael Merger and Philipp Harter and {AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium} and Bente Lund",

note = "Member of Study group",

year = "2016",

month = jan,

doi = "10.1016/S1470-2045(15)00366-6",

language = "English",

volume = "17",

pages = "78--89",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "TheLancet Publishing Group",

number = "1",

}

du Bois, A, Kristensen, G, Ray-Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, Del Campo, JM, Ottevanger, P, Heubner, M, Minarik, T, Sevin, E, de Gregorio, N, Bidziński, M, Pfisterer, J, Malander, S, Hilpert, F, Mirza, MR, Scambia, G, Meier, W, Nicoletto, MO, Bjørge, L, Lortholary, A, Sailer, MO, Merger, M, Harter, P & AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium 2016, 'Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial', Lancet Oncology, bind 17, nr. 1, s. 78-89. https://doi.org/10.1016/S1470-2045(15)00366-6

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12) : a randomised, double-blind, placebo-controlled phase 3 trial. / du Bois, Andreas; Kristensen, Gunnar; Ray-Coquard, Isabelle; Reuss, Alexander; Pignata, Sandro; Colombo, Nicoletta; Denison, Ursula; Vergote, Ignace; Del Campo, Jose M; Ottevanger, Petronella; Heubner, Martin; Minarik, Thomas; Sevin, Emmanuel; de Gregorio, Nikolaus; Bidziński, Mariusz; Pfisterer, Jacobus; Malander, Susanne; Hilpert, Felix; Mirza, Mansoor Raza; Scambia, Giovanni; Meier, Werner; Nicoletto, Maria O; Bjørge, Line; Lortholary, Alain; Sailer, Martin Oliver; Merger, Michael; Harter, Philipp; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.

I: Lancet Oncology, Bind 17, Nr. 1, 01.2016, s. 78-89.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12)

T2 - a randomised, double-blind, placebo-controlled phase 3 trial

AU - du Bois, Andreas

AU - Kristensen, Gunnar

AU - Ray-Coquard, Isabelle

AU - Reuss, Alexander

AU - Pignata, Sandro

AU - Colombo, Nicoletta

AU - Denison, Ursula

AU - Vergote, Ignace

AU - Del Campo, Jose M

AU - Ottevanger, Petronella

AU - Heubner, Martin

AU - Minarik, Thomas

AU - Sevin, Emmanuel

AU - de Gregorio, Nikolaus

AU - Bidziński, Mariusz

AU - Pfisterer, Jacobus

AU - Malander, Susanne

AU - Hilpert, Felix

AU - Mirza, Mansoor Raza

AU - Scambia, Giovanni

AU - Meier, Werner

AU - Nicoletto, Maria O

AU - Bjørge, Line

AU - Lortholary, Alain

AU - Sailer, Martin Oliver

AU - Merger, Michael

AU - Harter, Philipp

AU - AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium

A2 - Lund, Bente

N1 - Member of Study group

PY - 2016/1

Y1 - 2016/1

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Anemia

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Carcinoma

KW - Cytoreduction Surgical Procedures

KW - Diarrhea

KW - Disease Progression

KW - Disease-Free Survival

KW - Double-Blind Method

KW - Fallopian Tube Neoplasms

KW - Female

KW - Humans

KW - Indoles

KW - Intention to Treat Analysis

KW - Middle Aged

KW - Neoplasm Staging

KW - Neutropenia

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Peritoneal Neoplasms

KW - Response Evaluation Criteria in Solid Tumors

KW - Thrombocytopenia

KW - Young Adult

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/S1470-2045(15)00366-6

DO - 10.1016/S1470-2045(15)00366-6

M3 - Journal article

C2 - 26590673

VL - 17

SP - 78

EP - 89

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 1

ER -